Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

BRAF mutation predicts survival after immunotherapy across multiple cancer types.

Cancer treatment and research communications - 1 Jan 2026

Zhou Shaojun, Ge Weiting, Cai Wen

Abstract excerpt

Recently studies in selected tumors suggested that BRAF mutation may associates with survival benefit from immune checkpoint inhibitor (ICI) therapy. To broadly investigate this association at a pan-cancer level, we analyzed two independent ICI treatment cohorts (MSKCC: n = 1630, and Dana-Farber: n = 249). Patients with BRAF-mutant tumors exhibit better overall survival in the MSKCC cohort (Hazard ratio [HR] =...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Aged
Share to BRAF gene
Share to Immune Checkpoint Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Immunotherapy

Share to Mutation

Share to Neoplasms

Share to Prognosis

Share to Proto-Oncogene Proteins B-raf

Source

Identifiers

PMID: 42034597
DOI: 10.1016/j.ctarc.2026.101215

Genes

BRAF

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

BRAF mutation predicts survival after immunotherapy across multiple cancer types.PMID 42034597Read ↗

A mutational signature and significantly mutated driver genes associated with immune checkpoint inhibitor response across multiple cancers.Semantic proximity Read ↗

TP53/BRAF mutation as an aid in predicting response to immune-checkpoint inhibitor across multiple cancer types.Semantic proximity Read ↗

A mutation-based gene set predicts survival benefit after immunotherapy across multiple cancers and reveals the immune response landscape.Semantic proximity Read ↗

Tumor mutational load predicts survival after immunotherapy across multiple cancer typesSemantic proximity Read ↗

The immune response-related genomic alterations in patients with malignant melanoma.Semantic proximity Read ↗

The association between tumor mutational burden and prognosis is dependent on treatment context.Semantic proximity Read ↗

Somatic mutational landscape reveals mutational signatures and significantly mutated genes of cancer immunotherapeutic outcome and sex disparities.Semantic proximity Read ↗

Improved prediction of immune checkpoint blockade efficacy across multiple cancer types.Semantic proximity Read ↗

Cancer-specific associations of driver genes with immunotherapy outcomeSemantic proximity Read ↗

SETBP1 mutation determines sensitivity to immune checkpoint inhibitors in melanoma and NSCLC.Semantic proximity Read ↗

mTOR pathway gene mutations predict response to immune checkpoint inhibitors in multiple cancers.Semantic proximity Read ↗

Identification of NOTCH4 mutation as a response biomarker for immune checkpoint inhibitor therapy.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.